Final overall survival (OS) data of sintilimab plus pemetrexed (SPP) and platinum as first-line (1L) treatment for locally advanced or metastatic nonsquamous NSCLC (AMnsqNSCLC) in the phase III ORIENT-11 study

被引：4
|
作者：
Yang, Y. [1 ]
Wang, Z. [2 ]
Fang, J. [3 ]
Yu, Q. [4 ]
Han, B. [5 ]
Cang, S. [6 ]
Chen, G. [7 ]
Mei, X. [8 ]
Yang, Z. [9 ]
Stefaniak, V. [10 ]
Lin, Y. [10 ]
Wang, S. [11 ]
Zhang, W. [11 ]
Sun, L. [11 ]
Zhang, Y. [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou, Peoples R China
[2] Shandong Canc Hosp, Jinan, Shandong, Peoples R China
[3] Peking Univ Canc Hosp, Beijing, Peoples R China
[4] Guangxi Med Univ, Affiliated Tumor Hosp, Nanning, Peoples R China
[5] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Pulm Med Dept, Shanghai, Peoples R China
[6] Zhengzhou Univ, Henan Prov Hosp, Zhengzhou, Peoples R China
[7] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[8] Anhui Prov Hosp, Hefei, Peoples R China
[9] Guangdong Med Univ, Affiliated Hosp, Zhanjiang, Peoples R China
[10] Eli Lilly & Co, Indianapolis, IN 46285 USA
[11] Innovent Biol Inc, Suzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.013
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4MO
引用
收藏
页码：S28 / S28
页数：1
相关论文
共 50 条
  • [31] First-line (1L) maintenance therapy with niraparib (nira) plus pembrolizumab (pembro) vs placebo plus pembro in advanced/metastatic non-small cell lung cancer (NSCLC): Phase III ZEAL-1L study
    Ramalingam, S. S.
    de Castro, G., Jr.
    Garassino, M. C. C.
    Mazieres, J.
    Sanborn, R. E.
    Smit, E. F. F.
    Spigel, D. R.
    Thomas, M.
    Velcheti, V.
    Zhi, E.
    Whipple Neibauer, M.
    Stojadinovic, A.
    Peters, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S1030 - S1032
  • [32] Prognostic factors for Overall Survival (OS) in patients receiving First-line (1L) Nivolumab plus Ipilimumab (NIVO plus IPI) for advanced/metastatic Renal Cell Carcinoma (aRCC) in a real-world setting in Germany
    Bedke, J.
    Gruenwald, V.
    Mueller-Huesmann, H.
    Belz, H.
    Von Der Heyde, E.
    Boegemann, M.
    Strauss, A.
    Vaz, L.
    Bluhmki, T.
    Herber, M.
    Groetzinger, S.
    Grimm, M-O.
    EUROPEAN UROLOGY, 2024, 85 : S1844 - S1845
  • [33] PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small-Cell Lung Cancer
    Reck, Martin
    Paz-Ares, Luis G.
    de Marinis, Filippo
    Molinier, Olivier
    Sahoo, Tarini Prasad
    Laack, Eckart
    John, William
    Zimmermann, Annamaria H.
    Visseren-Grul, Carla
    Gridelli, Cesare
    JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (02) : 205 - 213
  • [34] Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC
    Mok, T. S. K.
    Wu, Y-L.
    Kudaba, I.
    Kowalski, D. M.
    Cho, B. C.
    Turna, H. Z.
    de Castro, G., Jr.
    Srimuninnimit, V.
    Laktionov, K. K.
    Bondarenko, I.
    Kubota, K.
    Caglevic, C.
    Karaszewska, B.
    Dang, T.
    Yin, L.
    Penrod, J.
    Lopes, G.
    ANNALS OF ONCOLOGY, 2019, 30 : 38 - 38
  • [35] PARAMOUNT: DESCRIPTIVE SUBGROUP ANALYSES OF FINAL OVERALL SURVIVAL (OS) FOR THE PHASE III STUDY OF MAINTENANCE PEMETREXED (PEM) VERSUS PLACEBO (PLB) FOLLOWING INDUCTION TREATMENT WITH PEM PLUS CISPLATIN (CIS) FOR ADVANCED NONSQUAMOUS (NS) NON-SMALL CELL LUNG CANCER (NSCLC)
    Reck, M.
    Paz-Ares, L.
    De Marinis, F.
    Molinier, O.
    Sahoo, T. Prasad
    Laack, E.
    John, W.
    Zimmermann, A.
    Visseren-Grul, C. M.
    Gridelli, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 404 - 404
  • [36] First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study
    Yang, James Chih-Hsin
    Srimuninnimit, Vichien
    Ahn, Myung-Ju
    Lin, Chia-Chi
    Kim, Sang-We
    Tsai, Chun-Ming
    Mok, Tony
    Orlando, Mauro
    Puri, Tarun
    Wang, Xin
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (03) : 370 - 379
  • [37] Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer
    Pereira J.R.
    Cheng R.
    Orlando M.
    Kim J.-H.
    Barraclough H.
    Drugs in R&D, 2013, 13 (4) : 289 - 296
  • [38] The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer
    Gridelli, Cesare
    Maione, Paolo
    Rossi, Antonio
    REVIEWS ON RECENT CLINICAL TRIALS, 2013, 8 (01) : 23 - 28
  • [39] Phase II study of pembrolizumab (pembro) plus platinum doublet chemotherapy and radiotherapy as first-line therapy for unresectable, locally advanced stage III NSCLC: KEYNOTE-799.
    Jabbour, Salma K.
    Lee, Ki Hyeong
    Frost, Nicolaj
    Kowalski, Dariusz
    Breder, Valeriy Vladimirovich
    Pollock, Theodore
    Reguart, Noemi
    Houghton, Baerin
    Quantin, Xavier
    Keller, Steven M.
    Liu, Hong
    Piperdi, Bilal
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Updated overall survival outcomes from a randomized, double-blind phase III study of sintilimab versus placebo in combination with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma (ORIENT-15)
    Lu, Zhihao
    Wang, Junye
    Shu, Yongqian
    Kong, Li
    Wang, Buhai
    Yang, Lei
    Cao, Guochun
    Sun, Guogui
    Ji, Yinghua
    Liu, Hu
    Cui, Tongjian
    Qiu, Wensheng
    Zaanan, Aziz
    Cid, Roberto Pazo
    Zhou, Hui
    Sun, Xing
    Wang, Yan
    Chen, Yuling
    Li, Haoyuan
    Zhang, Lishi
    Shen, Lin
    CANCER RESEARCH, 2023, 83 (08)
12345